NCT04017130View on ClinicalTrials.gov

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
DRUG

MT-0169

MT-0169 intravenous infusion.

Trial Locations (7)

30342

Northside Hospital, Atlanta

32224

Mayo Clinic - Jacksonville, Jacksonville

33136

Miami University, Miami

37203

Vanderbilt University Medical Center- Ingram Cancer Center, Nashville

43201

The Ohio State University, Columbus

55905

Mayo Clinic - Rochester, Rochester

90033

University of Southern California, Los Angeles

Sponsors
All Listed Sponsors
lead

Molecular Templates, Inc.

INDUSTRY